粒子線治療市場：タイプ別（陽子線治療、重粒子線治療）、製品別（サイクロトロン、シンクロトロン、シンクロサイクロトロン）、サービス別、システム別（シングルルーム、マルチルーム）、がんタイプ別（小児がん、前立腺がん）、用途別（治療、研究）-2028年までの世界予測

Particle Therapy Market by Type (Proton Therapy, Heavy Ion), Products (Cyclotron, Synchrotron, Synchrocyclotron), Services, System (Single-room, Multi-room), Cancer Type (Pediatric, Prostate), Application (Treatment, Research) - Global Forecast to 2028

世界の粒子線治療市場は、2023年の7億米ドルから2028年には11億米ドルに達し、予測期間中のCAGRは8.2％で成長すると予測されている。粒子線治療市場の急成長が予測される背景には、がんの増加、技術の進歩、がん... もっと見る

出版社	出版年月	電子版価格	ページ数	図表数	言語
MarketsandMarkets マーケッツアンドマーケッツ	2023年11月9日	US$4,950 シングルユーザライセンスライセンス・価格情報注文方法はこちら	196	207	英語

日本語のページは自動翻訳を利用し作成しています。

サマリー

世界の粒子線治療市場は、2023年の7億米ドルから2028年には11億米ドルに達し、予測期間中のCAGRは8.2％で成長すると予測されている。粒子線治療市場の急成長が予測される背景には、がんの増加、技術の進歩、がんに関する個人の意識の向上、がん研究への資金提供の増加などがある。

「2023年から2028年の予測期間において、小児アプリケーション分野が最も高いCAGRを記録する。
粒子線治療市場は、がんの種類に基づき、小児がん、乳がん、肺がん、前立腺がん、頭頸部がん、その他のがんに区分される。2022年には小児がんが最も高い成長率を示している。小児がんの増加は、遺伝的素因、乳幼児の発育要因、未熟な免疫系、環境暴露、母親の要因、細胞の脆弱性などが原因となっている。

"アジア太平洋地域は予測期間中に市場の著しい成長率を記録する"
予測期間2023-2028年において、APAC地域は予測期間中に市場で著しい成長率を記録すると予想される。アジア太平洋地域は、インド、中国、日本、オーストラリア、韓国、RoAPACで構成される。アジア太平洋（APAC）地域は、粒子線治療市場の市場成長率が大幅に上昇している。この成長にはいくつかの要因がある：
APAC諸国では人口動態が成熟しつつあり、治療関連の副作用を最小限に抑えた効率的ながん治療法が求められている。粒子線治療市場の精密さ主導の特性との共鳴は、市場展望を拡大する上で極めて重要な役割を果たしている。
APACの病院では多言語による患者ケアを提供しており、粒子線治療市場のような先進治療へのアクセスも容易であることから、この地域は特に多様な患者の間で独特の魅力を放っている。このような言語的な包括性と最先端の医療介入の融合は、この地域の好まれている医療目的地としての望ましさを著しく高め、その結果、医療市場ランドスケープにおける競争力を強化し、粒子線治療市場の隆盛を後押ししている。

本レポートの主な参加企業の内訳は以下の通りである：
- 企業タイプ別ティア1-40％、ティア2-30％、ティア3-30
- 役職別Cレベル-27％、ディレクターレベル-18％、その他-55
- 地域別北米-50%、欧州-20%、アジア太平洋地域-15%、中南米-10%、中東・アフリカ-5

粒子線治療市場の主要企業は、Varian Medical Systems, Inc.（米国）、IBA Worldwide（EU）、日立製作所（日本）などである。

調査範囲

- 本レポートでは、粒子線治療市場をタイプ、システム、製品、用途、癌タイプ、地域に基づいて調査しています。
- 市場成長に影響を与える要因（促進要因、阻害要因、機会、課題など）を分析しています。
- 利害関係者向けに市場の機会と課題を評価し、市場リーダー向けに競争環境の詳細を提供しています。
- 微小市場の成長動向、展望、世界の粒子線治療市場への貢献に関して調査しています。
- 主要5地域に関して市場セグメントの収益を予測しています。

レポート購入の主な利点

本レポートは、包括的なデータの徹底的な分析を通じて、粒子線治療市場における投資評価の実行可能性について、市場リーダー/新規参入企業/小規模企業の助けとなり、それによって強固なリスク評価が容易になり、十分な情報に基づいた投資決定が可能になります。用途、エンドユーザー、地域などの次元を網羅した綿密な市場区分により、的確なセグメントターゲティングのためのテーラーメイドの洞察が得られます。また、極めて重要なトレンド、成長触媒、課題、展望を網羅的に評価し、鋭い洞察力で戦略的意思決定を後押しします。
本レポートは、以下のポイントに関する洞察を提供しています：
- 粒子線治療市場の成長に影響を与える主な促進要因（がん患者人口の増加、がん管理に対する政府の取り組みの増加、放射線治療による非侵襲的治療の進歩）、阻害要因（熟練した放射線科医/腫瘍医の不足、粒子線治療の高コスト、治療のための画像技術の複雑さ）、機会（新興国における主要企業の拡大、発展途上国における医療費の増加）、課題（代替技術の利用可能性）についての分析を掲載しています。
- 製品開発/イノベーション：粒子線治療市場における今後の技術、研究開発活動、新製品・サービスの発売に関する詳細な洞察。
- 市場開発：有利な市場に関する包括的情報 - 当レポートでは、さまざまな地域の粒子線治療市場を分析しています。
- 市場の多様化：粒子線治療市場における新製品、未開拓地域、最近の開発、投資に関する詳細な情報
- 競合評価：Varian Medical Systems社（米国）、IBA Worldwide社（EU）、日立製作所（日本）などの主要企業の市場シェア、成長戦略、サービス内容を詳細に評価。

ページTOPに戻る

1 INTRODUCTION 28
1.1 STUDY OBJECTIVES 28
1.2 MARKET DEFINITION 28
1.3 INCLUSIONS & EXCLUSIONS 29
1.4 MARKET SCOPE 29
1.4.1 MARKETS COVERED 29
1.4.2 REGIONS COVERED 30
1.4.3 YEARS CONSIDERED 30
1.4.4 CURRENCY CONSIDERED 31
TABLE 1 EXCHANGE RATES UTILIZED FOR CONVERSION TO USD 31
1.5 STAKEHOLDERS 31
1.6 SUMMARY OF CHANGES 31
1.6.1 RECESSION IMPACT: PARTICLE THERAPY MARKET 32
2 RESEARCH METHODOLOGY 33
2.1 RESEARCH DATA 33
FIGURE 1 RESEARCH DESIGN 33
2.1.1 SECONDARY DATA 33
2.1.1.1 Key data from secondary sources 34
2.1.2 PRIMARY DATA 35
2.1.2.1 Key primary sources 35
2.1.2.2 Key data from primary sources 36
2.1.2.3 Breakdown of primaries 36
FIGURE 2 BREAKDOWN OF PRIMARY INTERVIEWS (SUPPLY-SIDE): BY COMPANY TYPE, DESIGNATION, AND REGION 36
FIGURE 3 BREAKDOWN OF PRIMARY INTERVIEWS (DEMAND-SIDE): BY END USER, DESIGNATION, AND REGION 37
2.1.2.4 Key industry insights 37
2.2 MARKET SIZE ESTIMATION 38
FIGURE 4 MARKET SIZE ESTIMATION: REVENUE SHARE ANALYSIS, 2022 39
FIGURE 5 SUPPLY-SIDE ANALYSIS 39
FIGURE 6 TOP-DOWN APPROACH 40
FIGURE 7 CAGR PROJECTIONS FROM ANALYSIS OF DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES 41
FIGURE 8 CAGR PROJECTIONS 42
2.3 MARKET BREAKDOWN AND DATA TRIANGULATION 43
FIGURE 9 DATA TRIANGULATION METHODOLOGY 43
2.4 RESEARCH LIMITATIONS 44
2.4.1 SCOPE-RELATED LIMITATIONS 44
2.4.2 METHODOLOGY-RELATED LIMITATIONS 44
2.5 RISK ASSESSMENT 44
2.6 STUDY ASSUMPTIONS 45
2.6.1 IMPACT OF RECESSION ON PARTICLE THERAPY MARKET 45
3 EXECUTIVE SUMMARY 46
FIGURE 10 PARTICLE THERAPY MARKET, BY TYPE, 2023 VS. 2028 (USD MILLION) 46
FIGURE 11 PARTICLE THERAPY MARKET, BY PRODUCT & SERVICE, 2023 VS. 2028 (USD MILLION) 47
FIGURE 12 PARTICLE THERAPY PRODUCTS MARKET, BY TYPE, 2023 VS. 2028 (USD MILLION) 47
FIGURE 13 PARTICLE THERAPY MARKET, BY SYSTEM, 2023 VS. 2028 (USD MILLION) 48
FIGURE 14 PARTICLE THERAPY MARKET, BY CANCER TYPE, 2023 VS. 2028 (USD MILLION) 49
FIGURE 15 PARTICLE THERAPY MARKET, BY APPLICATION, 2023 VS. 2028 (USD MILLION) 49
FIGURE 16 GEOGRAPHICAL SNAPSHOT OF PARTICLE THERAPY MARKET 50
4 PREMIUM INSIGHTS 51
4.1 PARTICLE THERAPY MARKET OVERVIEW 51
FIGURE 17 INCREASING PREVALENCE OF CANCER TO DRIVE MARKET 51
4.2 REGIONAL MIX: PARTICLE THERAPY MARKET 52
FIGURE 18 ASIA PACIFIC TO REGISTER HIGHEST GROWTH RATE DURING STUDY PERIOD 52
4.3 ASIA PACIFIC: PARTICLE THERAPY MARKET, BY TYPE AND COUNTRY (2022) 53
FIGURE 19 PROTON THERAPY ACCOUNTED FOR LARGEST SHARE OF ASIA PACIFIC MARKET IN 2022 53
4.4 PARTICLE THERAPY MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES 54
FIGURE 20 CHINA TO REGISTER HIGHEST CAGR DURING FORECAST PERIOD 54
4.5 DEVELOPED VS. EMERGING ECONOMIES: PARTICLE THERAPY MARKET 54
FIGURE 21 EMERGING ECONOMIES TO REGISTER HIGHER GROWTH DURING FORECAST PERIOD 54
5 MARKET OVERVIEW 55
5.1 INTRODUCTION 55
FIGURE 22 PARTICLE THERAPY MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES 55
5.1.1 DRIVERS 56
5.1.1.1 Advantages of particle therapy over photon therapy 56
5.1.1.2 Growing prevalence of cancer 56
5.1.1.3 Rising adoption of particle therapy in clinical trials 57
5.1.1.4 Increasing number of particle therapy centers worldwide 57
5.1.1.5 Technological advancements 57
5.1.2 RESTRAINTS 58
5.1.2.1 Infrastructural challenges in healthcare facilities 58
5.1.2.2 Affordability and accessibility of treatments 58
5.1.2.3 Unfavorable reimbursement policies and limited insurance coverage for particle therapy 59
5.1.3 OPPORTUNITIES 59
5.1.3.1 Growth potential of emerging economies 59
5.1.4 CHALLENGES 60
5.1.4.1 Difficulties in visualizing tumors during particle therapy procedures 60
5.1.4.2 Potential for unwanted radiation exposure 60
5.2 ECOSYSTEM/MARKET MAP 61
FIGURE 23 PARTICLE THERAPY MARKET: ECOSYSTEM ANALYSIS 61
5.3 PRICING ANALYSIS 61
5.4 SUPPLY CHAIN ANALYSIS 62
FIGURE 24 SUPPLY CHAIN ANALYSIS: PARTICLE THERAPY MARKET 62
5.5 PATENT ANALYSIS 63
5.5.1 PATENT PUBLICATION TRENDS FOR PARTICLE THERAPY MARKET 63
FIGURE 25 TOTAL PATENTS GRANTED FROM 2012–2022 64
FIGURE 26 TOP PATENT APPLICANTS IN PARTICLE THERAPY 64
FIGURE 27 TOP PATENT OWNERS IN PARTICLE THERAPY 65
5.6 VALUE CHAIN ANALYSIS 65
FIGURE 28 PARTICLE THERAPY MARKET: VALUE CHAIN ANALYSIS 66
5.7 TECHNOLOGY ANALYSIS 66
5.8 KEY CONFERENCES & EVENTS IN 2023–2024 67
5.9 REGULATORY LANDSCAPE 68
TABLE 2 NORTH AMERICA: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 68
TABLE 3 EUROPE: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 68
TABLE 4 ASIA PACIFIC: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 69
TABLE 5 REST OF THE WORLD: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 69
TABLE 6 REGULATORY STANDARDS/APPROVALS REQUIRED FOR PARTICLE THERAPY PRODUCTS BY COUNTRY/REGION 70
5.10 REIMBURSEMENT ANALYSIS 70
TABLE 7 MEDICAL REIMBURSEMENT CODES FOR PARTICLE THERAPY PROCEDURES IN US, 2022 70
5.11 TRADE ANALYSIS 71
TABLE 8 INSTALLED BASE OF RADIOTHERAPY DEVICES 71
5.12 PORTER’S FIVE FORCES ANALYSIS 71
TABLE 9 PARTICLE THERAPY MARKET: PORTER’S FIVE FORCES ANALYSIS 71
5.12.1 THREAT OF NEW ENTRANTS 71
5.12.2 THREAT OF SUBSTITUTES 72
5.12.3 BARGAINING POWER OF SUPPLIERS 72
5.12.4 BARGAINING POWER OF BUYERS 72
5.12.5 DEGREE OF COMPETITION 72
5.13 KEY STAKEHOLDERS & BUYING CRITERIA 72
5.13.1 KEY STAKEHOLDERS IN BUYING PROCESS 72
FIGURE 29 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS FOR TOP THREE APPLICATIONS 72
TABLE 10 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS FOR TOP THREE APPLICATIONS (%) 73
5.13.2 BUYING CRITERIA 73
FIGURE 30 KEY BUYING CRITERIA FOR TOP THREE APPLICATIONS 73
TABLE 11 KEY BUYING CRITERIA FOR TOP THREE APPLICATIONS 73
5.14 CASE STUDY ANALYSIS 74
TABLE 12 CASE STUDY: ENHANCING PATIENT SAFETY—RT’S ROLE IN MINIMIZING RADIATION RISK IN AN ELDERLY PATIENT (90-YEAR-OLD FEMALE WITH A MEDICALLY INOPERABLE EARLY-STAGE NSCLC) 74
5.15 TRENDS/DISRUPTIONS IMPACTING CUSTOMER’S BUSINESS 74
FIGURE 31 EMERGING TRENDS AND OPPORTUNITIES AFFECTING FUTURE REVENUE MIX 74
6 PARTICLE THERAPY MARKET, BY PRODUCT & SERVICE 75
6.1 INTRODUCTION 76
TABLE 13 PARTICLE THERAPY MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION) 76
6.2 PRODUCTS 76
TABLE 14 PARTICLE THERAPY PRODUCTS MARKET, BY TYPE, 2021–2028 (USD MILLION) 76
TABLE 15 PARTICLE THERAPY PRODUCTS MARKET, BY REGION, 2021–2028 (USD MILLION) 77
6.2.1 CYCLOTRONS 77
6.2.1.1 Advantages offered by cyclotrons over other accelerators to drive market 77
TABLE 16 CYCLOTRONS MARKET, BY REGION, 2021–2028 (USD MILLION) 78
TABLE 17 NORTH AMERICA: CYCLOTRONS MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 78
TABLE 18 EUROPE: CYCLOTRONS MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 78
TABLE 19 ASIA PACIFIC: CYCLOTRONS MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 79
TABLE 20 LATIN AMERICA: CYCLOTRONS MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 79
6.2.2 SYNCHROTRONS 79
6.2.2.1 Increasing investments for development of synchrotron facilities to aid market growth 79
TABLE 21 SYNCHROTRONS MARKET, BY REGION, 2021–2028 (USD MILLION) 80
TABLE 22 NORTH AMERICA: SYNCHROTRONS MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 80
TABLE 23 EUROPE: SYNCHROTRONS MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 80
TABLE 24 ASIA PACIFIC: SYNCHROTRONS MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 81
TABLE 25 LATIN AMERICA: SYNCHROTRONS MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 81
6.2.3 SYNCHROCYCLOTRONS 81
6.2.3.1 High space requirements to limit adoption 81
TABLE 26 SYNCHROCYCLOTRONS MARKET, BY REGION, 2021–2028 (USD MILLION) 82
TABLE 27 NORTH AMERICA: SYNCHROCYCLOTRONS MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 82
TABLE 28 EUROPE: SYNCHROCYCLOTRONS MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 83
TABLE 29 ASIA PACIFIC: SYNCHROCYCLOTRONS MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 83
TABLE 30 LATIN AMERICA: SYNCHROCYCLOTRONS MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 84
6.3 SERVICES 84
6.3.1 AVAILABILITY OF WIDE RANGE OF SERVICES TO PROPEL MARKET 84
TABLE 31 PARTICLE THERAPY SERVICES MARKET, BY REGION, 2021–2028 (USD MILLION) 84
TABLE 32 NORTH AMERICA: PARTICLE THERAPY SERVICES MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 85
TABLE 33 EUROPE: PARTICLE THERAPY SERVICES MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 85
TABLE 34 ASIA PACIFIC: PARTICLE THERAPY SERVICES MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 86
TABLE 35 LATIN AMERICA: PARTICLE THERAPY SERVICES MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 86
7 PARTICLE THERAPY MARKET, BY TYPE 87
7.1 INTRODUCTION 88
TABLE 36 PARTICLE THERAPY MARKET, BY TYPE, 2021–2028 (USD MILLION) 88
7.2 PROTON THERAPY 88
7.2.1 GROWING ADOPTION AS PRIMARY TREATMENT FOR VARIOUS CANCER TYPES TO DRIVE MARKET 88
TABLE 37 PROTON THERAPY MARKET, BY REGION, 2021–2028 (USD MILLION) 89
7.3 HEAVY ION THERAPY 89
7.3.1 SLOWER GROWTH ATTRIBUTED TO EXPERIMENTAL PHASE ACROSS MANY REGIONS 89
TABLE 38 HEAVY ION THERAPY MARKET, BY REGION, 2021–2028 (USD MILLION) 90
8 PARTICLE THERAPY MARKET, BY SYSTEM 91
8.1 INTRODUCTION 92
TABLE 39 PARTICLE THERAPY MARKET, BY SYSTEM, 2021–2028 (USD MILLION) 92
8.2 MULTI-ROOM SYSTEMS 92
8.2.1 LOWER SHIELDING REQUIREMENTS AND FASTER BEAM-SWITCHING CAPABILITIES TO DRIVE INTEREST AMONG END USERS 92
TABLE 40 PARTICLE THERAPY MARKET FOR MULTI-ROOM SYSTEMS, BY REGION, 2021–2028 (USD MILLION) 93
8.3 SINGLE-ROOM SYSTEMS 93
8.3.1 COMPACT STRUCTURE AND REDUCED CAPITAL COST TO PROPEL GROWTH 93
TABLE 41 PARTICLE THERAPY MARKET FOR SINGLE-ROOM SYSTEMS, BY REGION, 2021–2028 (USD MILLION) 94
9 PARTICLE THERAPY MARKET, BY APPLICATION 95
9.1 INTRODUCTION 96
TABLE 42 PARTICLE THERAPY MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 96
9.2 TREATMENT APPLICATIONS 96
9.2.1 INTRODUCTION OF SMALL FOOTPRINT SINGLE-ROOM PARTICLE THERAPY CENTERS TO SUPPORT MARKET GROWTH 96
TABLE 43 PARTICLE THERAPY MARKET FOR TREATMENT APPLICATIONS, BY REGION, 2021–2028 (USD MILLION) 97
9.3 RESEARCH APPLICATIONS 97
9.3.1 INCREASING AVAILABILITY OF FUNDING FOR PARTICLE THERAPY-RELATED RESEARCH PROJECTS TO PROVIDE GROWTH OPPORTUNITIES 97
TABLE 44 PARTICLE THERAPY MARKET FOR RESEARCH APPLICATIONS, BY REGION, 2021–2028 (USD MILLION) 98
10 PARTICLE THERAPY MARKET, BY CANCER TYPE 99
10.1 INTRODUCTION 100
TABLE 45 PARTICLE THERAPY MARKET, BY CANCER TYPE, 2021–2028 (USD MILLION) 100
10.2 PEDIATRIC CANCER 100
10.2.1 INCREASING CASES OF PEDIATRIC CANCER TO PROPEL MARKET 100
TABLE 46 PARTICLE THERAPY MARKET FOR PEDIATRIC CANCER, BY REGION, 2021–2028 (USD MILLION) 101
10.3 PROSTATE CANCER 101
10.3.1 ADVANTAGES OFFERED BY PARTICLE THERAPY FOR TREATMENT OF PROSTATE CANCER TO DRIVE MARKET 101
TABLE 47 PARTICLE THERAPY MARKET FOR PROSTATE CANCER, BY REGION, 2021–2028 (USD MILLION) 102
10.4 LUNG CANCER 102
10.4.1 GROWING CLINICAL TESTING OF PROTON THERAPY FOR LUNG CANCER TO DRIVE MARKET 102
TABLE 48 PARTICLE THERAPY MARKET FOR LUNG CANCER, BY REGION, 2021–2028 (USD MILLION) 102
10.5 BREAST CANCER 103
10.5.1 LIMITED RADIATION EXPOSURE WITH REDUCED SIDE-EFFECTS TO INCREASE ADOPTION OF PARTICLE THERAPY 103
TABLE 49 PARTICLE THERAPY MARKET FOR BREAST CANCER, BY REGION, 2021–2028 (USD MILLION) 103
10.6 HEAD & NECK CANCER 103
10.6.1 USE OF PENCIL-BEAM SCANNING FOR PROTON THERAPY TO SUPPORT MARKET GROWTH 103
TABLE 50 PARTICLE THERAPY MARKET FOR HEAD & NECK CANCER, BY REGION, 2021–2028 (USD MILLION) 104
10.7 OTHER CANCERS 104
TABLE 51 PARTICLE THERAPY MARKET FOR OTHER CANCERS, BY REGION, 2021–2028 (USD MILLION) 104
11 PARTICLE THERAPY MARKET, BY REGION 105
11.1 INTRODUCTION 106
TABLE 52 PARTICLE THERAPY MARKET, BY REGION, 2021–2028 (USD MILLION) 106
11.2 NORTH AMERICA 106
11.2.1 NORTH AMERICA: RECESSION IMPACT 106
FIGURE 32 NORTH AMERICA: PARTICLE THERAPY MARKET SNAPSHOT 107
TABLE 53 NORTH AMERICA: PARTICLE THERAPY MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 108
TABLE 54 NORTH AMERICA: PARTICLE THERAPY MARKET, BY TYPE, 2021–2028 (USD MILLION) 108
TABLE 55 NORTH AMERICA: PARTICLE THERAPY MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION) 108
TABLE 56 NORTH AMERICA: PARTICLE THERAPY PRODUCTS MARKET, BY TYPE, 2021–2028 (USD MILLION) 109
TABLE 57 NORTH AMERICA: PARTICLE THERAPY MARKET, BY SYSTEM, 2021–2028 (USD MILLION) 109
TABLE 58 NORTH AMERICA: PARTICLE THERAPY MARKET, BY CANCER TYPE, 2021–2028 (USD MILLION) 109
TABLE 59 NORTH AMERICA: PARTICLE THERAPY MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 110
11.2.2 US 110
11.2.2.1 Growing number of particle therapy centers to drive market growth 110
TABLE 60 US: MACROECONOMIC INDICATORS 111
TABLE 61 US: PARTICLE THERAPY MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION) 111
TABLE 62 US: PARTICLE THERAPY PRODUCTS MARKET, BY TYPE, 2021–2028 (USD MILLION) 111
11.2.3 CANADA 112
11.2.3.1 Government initiative to include particle therapy as treatment method to boost market 112
TABLE 63 CANADA: MACROECONOMIC INDICATORS 112
TABLE 64 CANADA: PARTICLE THERAPY MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION) 113
TABLE 65 CANADA: PARTICLE THERAPY PRODUCTS MARKET, BY TYPE, 2021–2028 (USD MILLION) 113
11.3 EUROPE 113
11.3.1 EUROPE: RECESSION IMPACT 114
TABLE 66 EUROPE: PARTICLE THERAPY MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 114
TABLE 67 EUROPE: PARTICLE THERAPY MARKET, BY TYPE, 2021–2028 (USD MILLION) 114
TABLE 68 EUROPE: PARTICLE THERAPY MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION) 115
TABLE 69 EUROPE: PARTICLE THERAPY PRODUCTS MARKET, BY TYPE, 2021–2028 (USD MILLION) 115
TABLE 70 EUROPE: PARTICLE THERAPY MARKET, BY SYSTEM, 2021–2028 (USD MILLION) 115
TABLE 71 EUROPE: PARTICLE THERAPY MARKET, BY CANCER TYPE, 2021–2028 (USD MILLION) 116
TABLE 72 EUROPE: PARTICLE THERAPY MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 116
11.3.2 GERMANY 116
11.3.2.1 Increasing research on proton and heavy ion therapy to drive market growth 116
TABLE 73 GERMANY: MACROECONOMIC INDICATORS 117
TABLE 74 GERMANY: PARTICLE THERAPY MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION) 117
TABLE 75 GERMANY: PARTICLE THERAPY PRODUCTS MARKET, BY TYPE, 2021–2028 (USD MILLION) 117
11.3.3 FRANCE 118
11.3.3.1 Increasing healthcare expenditure to support particle therapy product adoption 118
TABLE 76 FRANCE: MACROECONOMIC INDICATORS 118
TABLE 77 FRANCE: PARTICLE THERAPY MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION) 119
TABLE 78 FRANCE: PARTICLE THERAPY PRODUCTS MARKET, BY TYPE, 2021–2028 (USD MILLION) 119
11.3.4 UK 119
11.3.4.1 Increasing acceptance of particle therapy techniques in cancer treatment to support market growth 119
TABLE 79 UK: MACROECONOMIC INDICATORS 120
TABLE 80 UK: PARTICLE THERAPY MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION) 120
TABLE 81 UK: PARTICLE THERAPY PRODUCTS MARKET, BY TYPE, 2021–2028 (USD MILLION) 121
11.3.5 ITALY 121
11.3.5.1 Increasing awareness activities to support market growth 121
TABLE 82 ITALY: MACROECONOMIC INDICATORS 121
TABLE 83 ITALY: PARTICLE THERAPY MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION) 122
TABLE 84 ITALY: PARTICLE THERAPY PRODUCTS MARKET, BY TYPE, 2021–2028 (USD MILLION) 122
11.3.6 SPAIN 122
11.3.6.1 Increasing number of conferences and government funding for cancer research to drive market 122
TABLE 85 SPAIN: MACROECONOMIC INDICATORS 123
TABLE 86 SPAIN: PARTICLE THERAPY MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION) 124
TABLE 87 SPAIN: PARTICLE THERAPY PRODUCTS MARKET, BY TYPE, 2021–2028 (USD MILLION) 124
11.3.7 REST OF EUROPE 124
TABLE 88 REST OF EUROPE: PARTICLE THERAPY MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION) 125
TABLE 89 REST OF EUROPE: PARTICLE THERAPY PRODUCTS MARKET, BY TYPE, 2021–2028 (USD MILLION) 125
11.4 ASIA PACIFIC 125
11.4.1 ASIA PACIFIC: RECESSION IMPACT 126
FIGURE 33 ASIA PACIFIC: PARTICLE THERAPY MARKET SNAPSHOT 127
TABLE 90 ASIA PACIFIC: PARTICLE THERAPY MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 128
TABLE 91 ASIA PACIFIC: PARTICLE THERAPY MARKET, BY TYPE, 2021–2028 (USD MILLION) 128
TABLE 92 ASIA PACIFIC: PARTICLE THERAPY MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION) 128
TABLE 93 ASIA PACIFIC: PARTICLE THERAPY PRODUCTS MARKET, BY TYPE, 2021–2028 (USD MILLION) 129
TABLE 94 ASIA PACIFIC: PARTICLE THERAPY MARKET, BY SYSTEM, 2021–2028 (USD MILLION) 129
TABLE 95 ASIA PACIFIC: PARTICLE THERAPY MARKET, BY CANCER TYPE, 2021–2028 (USD MILLION) 129
TABLE 96 ASIA PACIFIC: PARTICLE THERAPY MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 130
11.4.2 JAPAN 130
11.4.2.1 Increasing use of heavy ion therapy for cancer treatment to propel market 130
TABLE 97 JAPAN: MACROECONOMIC INDICATORS 131
TABLE 98 JAPAN: PARTICLE THERAPY MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION) 131
TABLE 99 JAPAN: PARTICLE THERAPY PRODUCTS MARKET, BY TYPE, 2021–2028 (USD MILLION) 131
11.4.3 CHINA 132
11.4.3.1 High cancer burden to drive market 132
TABLE 100 CHINA: MACROECONOMIC INDICATORS 132
TABLE 101 CHINA: PARTICLE THERAPY MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION) 133
TABLE 102 CHINA: PARTICLE THERAPY PRODUCTS MARKET, BY TYPE, 2021–2028 (USD MILLION) 133
11.4.4 INDIA 133
11.4.4.1 Improving research capabilities to support market growth 133
TABLE 103 INDIA: MACROECONOMIC INDICATORS 134
TABLE 104 INDIA: PARTICLE THERAPY MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION) 134
TABLE 105 INDIA: PARTICLE THERAPY PRODUCTS MARKET, BY TYPE, 2021–2028 (USD MILLION) 134
11.4.5 AUSTRALIA 135
11.4.5.1 Healthcare funding availability to boost market growth 135
TABLE 106 AUSTRALIA: MACROECONOMIC INDICATORS 135
TABLE 107 AUSTRALIA: PARTICLE THERAPY MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION) 135
TABLE 108 AUSTRALIA: PARTICLE THERAPY PRODUCTS MARKET, BY TYPE, 2021–2028 (USD MILLION) 136
11.4.6 SOUTH KOREA 136
11.4.6.1 Rising prevalence of cancer to drive market 136
TABLE 109 SOUTH KOREA: MACROECONOMIC INDICATORS 137
TABLE 110 SOUTH KOREA: PARTICLE THERAPY MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION) 137
TABLE 111 SOUTH KOREA: PARTICLE THERAPY PRODUCTS MARKET, BY TYPE, 2021–2028 (USD MILLION) 137
11.4.7 REST OF ASIA PACIFIC 138
TABLE 112 REST OF ASIA PACIFIC: PARTICLE THERAPY MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION) 138
TABLE 113 REST OF ASIA PACIFIC: PARTICLE THERAPY PRODUCTS MARKET, BY TYPE, 2021–2028 (USD MILLION) 138
11.5 LATIN AMERICA 139
11.5.1 LATIN AMERICA: RECESSION IMPACT 139
TABLE 114 LATIN AMERICA: PARTICLE THERAPY MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 139
TABLE 115 LATIN AMERICA: PARTICLE THERAPY MARKET, BY TYPE, 2021–2028 (USD MILLION) 140
TABLE 116 LATIN AMERICA: PARTICLE THERAPY MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION) 140
TABLE 117 LATIN AMERICA: PARTICLE THERAPY PRODUCTS MARKET, BY TYPE, 2021–2028 (USD MILLION) 140
TABLE 118 LATIN AMERICA: PARTICLE THERAPY MARKET, BY SYSTEM, 2021–2028 (USD MILLION) 141
TABLE 119 LATIN AMERICA: PARTICLE THERAPY MARKET, BY CANCER TYPE, 2021–2028 (USD MILLION) 141
TABLE 120 LATIN AMERICA: PARTICLE THERAPY MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 141
11.5.2 BRAZIL 142
11.5.2.1 Government initiates to propel market growth 142
TABLE 121 BRAZIL: MACROECONOMIC INDICATORS 142
TABLE 122 BRAZIL: PARTICLE THERAPY MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION) 143
TABLE 123 BRAZIL: PARTICLE THERAPY PRODUCTS MARKET, BY TYPE, 2021–2028 (USD MILLION) 143
11.5.3 MEXICO 143
11.5.3.1 Growing adoption of advanced medical technologies to drive market 143
TABLE 124 MEXICO: MACROECONOMIC INDICATORS 144
TABLE 125 MEXICO: PARTICLE THERAPY MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION) 144
TABLE 126 MEXICO: PARTICLE THERAPY PRODUCTS MARKET, BY TYPE, 2021–2028 (USD MILLION) 144
11.5.4 REST OF LATIN AMERICA 145
TABLE 127 REST OF LATIN AMERICA: PARTICLE THERAPY MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION) 145
TABLE 128 REST OF LATIN AMERICA: PARTICLE THERAPY PRODUCTS MARKET, BY TYPE, 2021–2028 (USD MILLION) 145
11.6 MIDDLE EAST & AFRICA 146
11.6.1 IMPROVING HEALTHCARE INFRASTRUCTURE AND INCREASING PUBLIC-PRIVATE INVESTMENTS TO DRIVE MARKET 146
11.6.2 MIDDLE EAST & AFRICA: RECESSION IMPACT 146
TABLE 129 MIDDLE EAST & AFRICA: PARTICLE THERAPY MARKET, BY TYPE, 2021–2028 (USD MILLION) 147
TABLE 130 MIDDLE EAST & AFRICA: PARTICLE THERAPY MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION) 147
TABLE 131 MIDDLE EAST & AFRICA: PARTICLE THERAPY PRODUCTS MARKET, BY TYPE, 2021–2028 (USD MILLION) 147
TABLE 132 MIDDLE EAST & AFRICA: PARTICLE THERAPY MARKET, BY SYSTEM, 2021–2028 (USD MILLION) 148
TABLE 133 MIDDLE EAST & AFRICA: PARTICLE THERAPY MARKET, BY CANCER TYPE, 2021–2028 (USD MILLION) 148
TABLE 134 MIDDLE EAST & AFRICA: PARTICLE THERAPY MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 148
12 COMPETITIVE LANDSCAPE 149
12.1 OVERVIEW 149
12.2 STRATEGIES ADOPTED BY KEY PLAYERS 150
FIGURE 34 KEY DEVELOPMENTS IN PARTICLE THERAPY MARKET 150
12.3 REVENUE SHARE ANALYSIS OF TOP MARKET PLAYERS 151
FIGURE 35 REVENUE ANALYSIS OF TOP PLAYERS IN PARTICLE THERAPY MARKET 151
12.4 MARKET SHARE ANALYSIS 152
FIGURE 36 MARKET SHARE ANALYSIS, BY KEY PLAYER, 2022 152
12.5 COMPANY EVALUATION MATRIX 153
12.5.1 STARS 153
12.5.2 EMERGING LEADERS 153
12.5.3 PERVASIVE PLAYERS 153
12.5.4 PARTICIPANTS 153
FIGURE 37 PARTICLE THERAPY MARKET: COMPANY EVALUATION MATRIX, 2022 154
12.6 COMPETITIVE BENCHMARKING FOR KEY PLAYERS 155
12.6.1 PARTICLE THERAPY MARKET: COMPANY FOOTPRINT 155
TABLE 135 OVERALL COMPANY FOOTPRINT (10 COMPANIES) 155
TABLE 136 TYPE FOOTPRINT (10 COMPANIES) 155
TABLE 137 PRODUCT & SERVICE FOOTPRINT (10 COMPANIES) 156
TABLE 138 SYSTEM FOOTPRINT (10 COMPANIES) 157
TABLE 139 CANCER TYPE FOOTPRINT (10 COMPANIES) 157
TABLE 140 APPLICATION FOOTPRINT (10 COMPANIES) 158
TABLE 141 REGIONAL FOOTPRINT (10 COMPANIES) 159
12.7 STARTUP/SME EVALUATION MATRIX 160
12.7.1 PROGRESSIVE COMPANIES 160
12.7.2 RESPONSIVE COMPANIES 160
12.7.3 DYNAMIC COMPANIES 160
12.7.4 STARTING BLOCKS 160
FIGURE 38 PARTICLE THERAPY MARKET: STARTUP/SME EVALUATION MATRIX, 2022 161
12.7.5 COMPETITIVE BENCHMARKING FOR STARTUPS/SMES 162
TABLE 142 OVERALL COMPANY FOOTPRINT 162
TABLE 143 TYPE FOOTPRINT 162
TABLE 144 PRODUCT & SERVICE FOOTPRINT 162
TABLE 145 SYSTEM FOOTPRINT 163
TABLE 146 CANCER TYPE FOOTPRINT 163
TABLE 147 APPLICATION FOOTPRINT 163
TABLE 148 REGIONAL FOOTPRINT 163
12.8 COMPETITIVE SCENARIOS & TRENDS 164
12.8.1 PRODUCT LAUNCHES & APPROVALS 164
TABLE 149 PARTICLE THERAPY MARKET: PRODUCT LAUNCHES & APPROVALS (JANUARY 2020−AUGUST 2023) 164
12.8.2 DEALS 164
TABLE 150 PARTICLE THERAPY MARKET: DEALS (JANUARY 2020−AUGUST 2023) 164
12.8.3 OTHER DEVELOPMENTS 166
TABLE 151 PARTICLE THERAPY MARKET: OTHER DEVELOPMENTS (JANUARY 2020−AUGUST 2023) 166
13 COMPANY PROFILES 167
13.1 KEY PLAYERS 167
(Business Overview, Products/Services/Solutions Offered, MnM View, Key Strengths and Right to Win, Strategic Choices Made, Weaknesses and Competitive Threats, Recent Developments)*
13.1.1 IBA WORLDWIDE 167
TABLE 152 IBA WORLDWIDE: BUSINESS OVERVIEW 167
FIGURE 39 IBA WORLDWIDE: COMPANY SNAPSHOT (2022) 168
13.1.2 VARIAN MEDICAL SYSTEMS, INC. 172
TABLE 153 VARIAN MEDICAL SYSTEMS, INC.: BUSINESS OVERVIEW 172
FIGURE 40 VARIAN MEDICAL SYSTEMS, INC.: COMPANY SNAPSHOT (2022) 173
13.1.3 HITACHI, LTD. 176
TABLE 154 HITACHI, LTD.: BUSINESS OVERVIEW 176
FIGURE 41 HITACHI, LTD.: COMPANY SNAPSHOT (2021) 177
13.1.4 MEVION MEDICAL SYSTEMS 179
TABLE 155 MEVION MEDICAL SYSTEMS: BUSINESS OVERVIEW 179
13.1.5 SUMITOMO HEAVY INDUSTRIES LTD. 182
TABLE 156 SUMITOMO HEAVY INDUSTRIES LTD.: BUSINESS OVERVIEW 182
FIGURE 42 SUMITOMO HEAVY INDUSTRIES LTD.: COMPANY SNAPSHOT (2021) 183
13.1.6 PROVISION HEALTHCARE, LLC 185
TABLE 157 PROVISION HEALTHCARE, LLC: BUSINESS OVERVIEW 185
13.1.7 TOSHIBA MEDICAL SYSTEMS CORPORATION 186
TABLE 158 TOSHIBA MEDICAL SYSTEMS CORPORATION: BUSINESS OVERVIEW 186
FIGURE 43 TOSHIBA MEDICAL SYSTEMS CORPORATION: COMPANY SNAPSHOT (2022) 187
13.1.8 OPTIVUS PROTON THERAPY, INC. 188
TABLE 159 OPTIVUS PROTON THERAPY, INC.: BUSINESS OVERVIEW 188
13.1.9 PROTOM INTERNATIONAL, INC. 189
TABLE 160 PROTOM INTERNATIONAL, INC.: BUSINESS OVERVIEW 189
13.1.10 ADVANCED ONCOTHERAPY PLC 190
TABLE 161 ADVANCED ONCOTHERAPY PLC: BUSINESS OVERVIEW 190
13.2 OTHER PLAYERS 191
13.2.1 DANFYSIK A/S 191
TABLE 162 DANFYSIK A/S: BUSINESS OVERVIEW 191
13.2.2 P-CURE, LTD. 192
TABLE 163 P-CURE, LTD.: BUSINESS OVERVIEW 192
13.2.3 PTW FREIBURG GMBH 193
TABLE 164 PTW FREIBURG GMBH: BUSINESS OVERVIEW 193
*Business Overview, Products/Services/Solutions Offered, MnM View, Key Strengths and Right to Win, Strategic Choices Made, Weaknesses and Competitive Threats, Recent Developments might not be captured in case of unlisted companies.
14 APPENDIX 194
14.1 DISCUSSION GUIDE 194
14.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 199
14.3 CUSTOMIZATION OPTIONS 201
14.4 RELATED REPORTS 201
14.5 AUTHOR DETAILS 202

ページTOPに戻る

Table of Contents

Summary

The global particle therapy market is projected to reach USD 1.1 billion by 2028 from USD 0.7 billion in 2023, growing at a CAGR of 8.2% during the forecast period. The projected surge in market growth for the Particle therapy market is seen due to an increase in cancers, advancements in technologies, and increased awareness among individuals regarding cancer, Increased funding for cancer research.

“The Paediatric application segment to register highest CAGR over the forecast period of 2023-2028.”
Based on the cancer type, the Particle therapy market is segmented into pediatric cancer, breast cancer, lung cancer, prostate cancer, head and neck, and other cancers. Pediatric cancer has witnessed the highest growth rate In 2022. The increase in Paediatric cancers can be seen due to the following reasons genetic predisposition, developmental factors in infants, immature immune system, environmental exposures, maternal factors, and cellular vulnerability among others.

“Asia Pacific to register significant growth rate in the market during the forecast period.”
For the forecasting period 2023-2028, the APAC region is expected to register a significant growth rate in the market during the forecast period. Asia Pacific comprises India, China, Japan, Australia, South Korea, and RoAPAC. The Asia-Pacific (APAC) region has witnessed a significant increase in the market growth rate for the particle therapy market. There are several drivers that contributed to this growth:
The maturing demographic profile observed in APAC countries accentuates the imperative for efficacious cancer treatment modalities characterized by minimized treatment-related adverse effects. This resonance with the precision-driven attributes of the Particle therapy market substantiates its pivotal role in enhancing the market landscape.
The incorporation of multilingual patient care offerings within APAC hospitals, combined with the accessibility to advanced treatments like the Particle therapy market, confers a unique allure to the region, particularly among a diverse patient spectrum. This fusion of linguistic inclusiveness and state-of-the-art medical interventions significantly enhances the region's desirability as a favored healthcare destination, thereby fortifying its competitive position within the healthcare market landscape and concomitantly propelling the prominence of particle therapy market.

A breakdown of the primary participants referred to for this report is provided below:
• By Company Type: Tier 1–40%, Tier 2–30%, and Tier 3– 30%
• By Designation: C-level–27%, Director-level–18%, and Others–55%
• By Region: North America–50%, Europe–20%, Asia Pacific–15%, Latin America–10%, and the Middle East & Africa–5%

Prominent players in particle therapy market are Varian Medical Systems, Inc.(US), IBA Worldwide(EU) and Hitachi (Japan) among others.

Research Coverage

• The report studies the Particle therapy market based on type, system, product, application, cancer type and region.
• The report analyzes factors (such as drivers, restraints, opportunities, and challenges) affecting the market growth.
• The report evaluates the opportunities and challenges in the market for stakeholders and provides details of the competitive landscape for market leaders.
• The report studies micro markets with respect to their growth trends, prospects, and contributions to the global Particle therapy market.
• The report forecasts the revenue of market segments with respect to five major regions.

Key Benefits of Buying the Report:

The report will help the market leaders/new entrants/smaller firms in this market with investment evaluation viability within the Particle therapy market through a thorough analysis of comprehensive data, thereby facilitating robust risk assessment and enabling well-informed investment determinations. Benefit from meticulous market segmentation encompassing application, end-user, and regional dimensions, affording tailored insights for precise segment targeting. The report also provides an all-encompassing evaluation of encapsulating pivotal trends, growth catalysts, challenges, and prospects, thereby empowering strategic decision-making with astute discernment.
The report provides insights on the following pointers:
• Analysis of key drivers (increasing prevalence of cancer patient population, Increasing government initiatives for cancer management, advancements in non-invasive treatments through radiation therapy), restraints (Dearth of skilled radiologist/oncologist, high cost of particle therapy, Complexity of imaging technology for treatments), opportunities (Expansion of key players in emerging countries, Rising healthcare expenditure across developing countries), and challenges (Availability of alternative technology) influencing the growth of the Particle therapy market
• Product Development/Innovation: Detailed insights on upcoming technologies, research & development activities, and new product & service launches in the particle therapy market.
• Market Development: Comprehensive information about lucrative markets – the report analyses the Particle therapy market across varied regions.
• Market Diversification: Exhaustive information about new products, untapped geographies, recent developments, and investments in the Particle therapy market
• Competitive Assessment: In-depth assessment of market shares, growth strategies, and service offerings of leading players like Varian Medical Systems, Inc.(US), IBA Worldwide(EU) and Hitachi (Japan) among others.

ページTOPに戻る

ご注文は、お電話またはWEBから承ります。お見積もりの作成もお気軽にご相談ください。

webからのご注文・お問合せはこちらのフォームから承ります

本レポートと同分野（医療機器）の最新刊レポート

MarketsandMarkets社のMedical Devices分野での最新刊レポート

本レポートと同じKEY WORD（cancer）の最新刊レポート

よくあるご質問

MarketsandMarkets社はどのような調査会社ですか?

マーケッツアンドマーケッツ（MarketsandMarkets）は通信、半導体、医療機器、エネルギーなど、幅広い市場に関する調査レポートを出版しています。また広範な市場を対象としたカスタム調査も行って... もっと見る

調査レポートの納品までの日数はどの程度ですか?

在庫のあるものは速納となりますが、平均的には 3-４日と見て下さい。
但し、一部の調査レポートでは、発注を受けた段階で内容更新をして納品をする場合もあります。
発注をする前のお問合せをお願いします。

注文の手続きはどのようになっていますか?

1)お客様からの御問い合わせをいただきます。
2)見積書やサンプルの提示をいたします。
3)お客様指定、もしくは弊社の発注書をメール添付にて発送してください。
4)データリソース社からレポート発行元の調査会社へ納品手配します。
5) 調査会社からお客様へ納品されます。最近は、pdfにてのメール納品が大半です。

お支払方法の方法はどのようになっていますか?

納品と同時にデータリソース社よりお客様へ請求書（必要に応じて納品書も）を発送いたします。
お客様よりデータリソース社へ（通常は円払い）の御振り込みをお願いします。
請求書は、納品日の日付で発行しますので、翌月最終営業日までの当社指定口座への振込みをお願いします。振込み手数料は御社負担にてお願いします。
お客様の御支払い条件が60日以上の場合は御相談ください。
尚、初めてのお取引先や個人の場合、前払いをお願いすることもあります。ご了承のほど、お願いします。

データリソース社はどのような会社ですか?

当社は、世界各国の主要調査会社・レポート出版社と提携し、世界各国の市場調査レポートや技術動向レポートなどを日本国内の企業・公官庁及び教育研究機関に提供しております。
世界各国の「市場・技術・法規制などの」実情を調査・収集される時には、データリソース社にご相談ください。
お客様の御要望にあったデータや情報を抽出する為のレポート紹介や調査のアドバイスも致します。

サマリー

目次

Summary

Table of Contents

ご注文は、お電話またはWEBから承ります。お見積もりの作成もお気軽にご相談ください。

本レポートと同分野（医療機器）の最新刊レポート

MarketsandMarkets社のMedical Devices分野での最新刊レポート

本レポートと同じKEY WORD（cancer）の最新刊レポート

よくあるご質問

MarketsandMarkets社はどのような調査会社ですか?

調査レポートの納品までの日数はどの程度ですか?

注文の手続きはどのようになっていますか?

お支払方法の方法はどのようになっていますか?

データリソース社はどのような会社ですか?